Atovaquone-Proguanil
Treatment for Malaria
Typical Dosage: Adults: 4 tablets (250mg atovaquone/100mg proguanil) once daily for 3 days
Effectiveness
95%
Safety Score
68%
Clinical Trials
36
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe
Treatment Details
Dosage Range
Adults: 4 tablets (250mg atovaquone/100mg proguanil) once daily for 3 days
Time to Effect
24-48 hours
Treatment Duration
3 days
Evidence Quality
HIGHConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75
Monitoring:$50
Side Effect Mgmt:$10
Total Annual:$135
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$142.1
Cost per Remission
$142.1
Comparison vs Artemether-Lumefantrine
Cost Difference
+$65/year
More expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
No dominance
Atovaquone-Proguanil Outcomes
for Malaria
Efficacy Outcomes
Overall Effectiveness
+95%
Response Rate
+95%
Remission Rate
+95%
Common Side Effects
Abdominal pain
+20%
Nausea/Vomiting
+15%
Diarrhea
+10%
Headache
+10%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
16 completed trials for Atovaquone-Proguanil in Malaria
Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension
NCT01858831COMPLETEDPHASE1
30 participants
INTERVENTIONAL
Kagoshima, Japan
Started: Apr 1, 2012
Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients
NCT00421473COMPLETEDPHASE4
79 participants
INTERVENTIONAL
Arnhem, Netherlands +4 more
Started: Mar 1, 2007
Weekly Dosing of Malarone ® for Prevention of Malaria
NCT00984256COMPLETEDPHASE2
35 participants
INTERVENTIONAL
Silver Spring, United States
Started: Sep 1, 2009
Atoguanil BA Study
NCT04866602COMPLETEDPHASE1
16 participants
INTERVENTIONAL
London, United Kingdom
Started: Nov 17, 2021
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
NCT00084227COMPLETEDPHASE2, PHASE3
244 participants
INTERVENTIONAL
Started: Jul 1, 2004
Chloroquine Alone or in Combination for Malaria in Children in Malawi
NCT00379821COMPLETEDPHASE3
640 participants
INTERVENTIONAL
Blantyre, Malawi
Started: Feb 1, 2007
Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function
NCT00444106COMPLETEDPHASE4
265 participants
INTERVENTIONAL
Tumaco, Colombia
Started: May 1, 2007
Ototoxicity of Artemether / Lumefantrine (Coartem) and Other Antimalarials
NCT00451139COMPLETEDPHASE4
INTERVENTIONAL
Jimma, Ethiopia
DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria
NCT02450578COMPLETEDPHASE1
22 participants
INTERVENTIONAL
Tübingen, Germany
Started: Oct 1, 2015
Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria
NCT01150344COMPLETEDPHASE4
317 participants
INTERVENTIONAL
Bobigny, France
Started: Jul 1, 2010
Safety and Efficacy Study of IV Artesunate to Treat Malaria
NCT00298610COMPLETEDPHASE2
30 participants
INTERVENTIONAL
Kisumu, Kenya
Started: Mar 1, 2006
Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis
NCT02080026COMPLETEDNA
15 participants
INTERVENTIONAL
Nijmegen, Netherlands
Started: Jun 1, 2014
A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
NCT06294912COMPLETEDPHASE1
16 participants
INTERVENTIONAL
South Brisbane, Australia
Started: Apr 18, 2024
Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis
NCT02858817COMPLETEDPHASE1
30 participants
INTERVENTIONAL
Started: Nov 28, 2016
Re-exposure of Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites
NCT01660854COMPLETEDNA
21 participants
INTERVENTIONAL
Leiden, Netherlands
Started: Jul 1, 2012
Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)
NCT05974267COMPLETEDPHASE2
192 participants
INTERVENTIONAL
Ouagadougou, Burkina Faso +3 more
Started: Nov 28, 2023
Showing 20 of 36 total trials